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Substitutionally inert ruthenium(II) polypyridyl complexes have been developed as DNA intercalating agents yet
cellular DNA damage responses to this binding modality are largely unexplored. Here, we show the nuclear-
targeting complex [Ru(phen)2(tpphz)]
2+ (phen ¼ 1,10-phenanthroline, tpphz ¼ tetrapyridophenazine)
generates rapid and pronounced stalling of replication fork progression in p53-deficient human
oesophageal cancer cells. In response, replication stress and double-strand break (DSB) DNA damage
response (DDR) pathways are activated and cell proliferation is inhibited by growth arrest. Moreover, mitotic
progression is compromised by [Ru(phen)2(tpphz)]
2+, where the generation of metaphase chromosome
spindle attachment failure results in spindle assembly checkpoint (SAC) activation. This dual mechanism of
action results in preferential growth inhibition of rapidly-proliferating oesophageal cancer cells with
elevated mitotic indices. In addition to these single-agent effects, [Ru(phen)2(tpphz)]
2+ functions as
a radiosensitizer with efficiency comparable to cisplatin, which occurs through a synergistic enhancement
of DNA damage. These results establish that DNA replication is the target for [Ru(phen)2(tpphz)]
2+ and
provide the first experimental evidence that ruthenium-based intercalation targets multiple genome
integrity pathways in cancer cells, thereby achieving enhanced selectivity compared to existing
DNA-damaging agents such as cisplatin.Introduction
Small molecules that interfere with DNA replication are widely-
used anti-cancer drugs and are oen employed in combination
therapy alongside ionising radiation (IR) to treat cancer.1,2 One
example of a clinical radiosensitizer is the platinum drug
cisplatin, which generates both inter and intra-strand Pt–DNA
cross-links and double-strand breaks (DSBs) that slow cell-cycle
progression through S-phase, exacerbating IR-induced DNA
damage.3,4 Although cisplatin-based chemoradiotherapy is
highly effective in many cases, oesophageal cancers are marked
by poor 5-year survival rates, typically <20%.5 Cisplatin is asso-
ciated with nephrotoxicity which limits dose escalation and
attempts to improve the outcome of patients with oesophageal
cancer using alternative DNA-damaging chemotherapy such ason Oncology, Department of Oncology,
artin.gill@oncology.ox.ac.uk; katherine.
ffield, Sheffield, UK
ity of Sheffield, Sheffield, UK
(ESI) available: Experimental methods,
I: 10.1039/c7sc03712k
hemistry 2018doxorubicin have been unsuccessful.6 Application of these
potent cytotoxic agents has also been hampered by the fact that
the majority (77%) of oesophageal cancers lack p53 function7
and therefore possess a reduced capacity to activate apoptotic
pathways in response to signicant DNA damage.8 Thus, less
toxic compounds that operate by alternative mechanisms of
action and can also function as radiosensitizers are required.
As typied by [Ru(bpy)2(dppz)]
2+ (bpy ¼ 2,2-bipyridine, dppz
¼ dipyridophenazine),9 substitutionally inert ruthenium(II)
polypyridyl complexes (RPCs) that interact with DNA solely via
intercalation have been developed as site- and structure-specic
luminescent DNA binding agents.9,10 Recent X-ray crystal
structures have provided molecular insight into RPC metallo-
intercalation in unprecedented detail.11–16 This includes
evidence that [Ru(phen)2(dppz)]
2+ (phen ¼ 1,10-phenanthro-
line) adopts multiple intercalative geometries12 and Ru(dppz)
semi-intercalation induces marked kinking of duplex DNA;11
a structural distortion similar to that observed following plati-
nation.17 Based on these studies with isolated DNA, the cellular
uptake and anti-cancer properties of RPCs have become of
increasing interest.18–20 However, despite the large number of
DNA-interactive RPCs that have now been screened for anti-Chem. Sci., 2018, 9, 841–849 | 841
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View Article Onlinecancer activity,21 few have unequivocally been shown to have
genomic DNA as their pharmacological target.22–24 As a result,
cellular DNA damage responses to lesions generated by RPC
mono-intercalation are completely unknown; a considerable
barrier to therapeutic development of this class of DNA-binding
agent. Moreover, while RPCs have generated much interest as
photosensitizers for photodynamic therapy (PDT),25–27 studies of
RPCs in combination with IR have been rare.23,28,29 This is
surprising as radiotherapy is a mainstay of cancer medicine:
high-energy X-rays or targeted radionuclide therapeutics have
a far greater depth of penetration in tissue than visible light and
radiotherapy is therefore capable of targeting a wider range of
cancers.2,30
[Ru(phen)2(tpphz)]
2+ (tpphz ¼ tetrapyrido[3,2-a:20,30-c:300,200-
h:2000,3000-j]phenazine), Ru1 (Fig. 1a), is a water-soluble hydro-
philic mono-intercalator (log P¼1.24, DNA Kb¼ 3 105 M1)
that shows in vitro anti-cancer activity31 and toxicity has been
established in murine models.32 Here, we present a detailed
characterisation of the cellular response to DNA damage
generated by Ru1 in p53-decient oesophageal cancer cells and
explore the complex in combination with IR.Fig. 1 (a) Structures of Ru1 and dppz. Ru1was used as the chloride salt
and as a mixture of L and D enantiomers. (b) Representative images of
DNA replication fibres in OE21 oesophageal cancer cells. CldU (first
pulse, 30 min) incorporation is shown in red, incorporated IdU (second
pulse, 30 min) in green. The second nucleotide (IdU) was either mock-
treated or incubated in the presence of Ru1 or dppz to determine
impact on DNA replication fork progression. Scale bar ¼ 10 mm. (c)
Quantification of IdU-labelled tract length in the presence of Ru1
(21 mM) or dppz (7 mM). Tract length was determined for >100 forks per
condition. Whisker box plots show mean values and data within the
10–90 percentile. (d) Quantification of completely stalled forks
(i.e. CldU tract only) for Ru1 or dppz treatment as in (b). Fork stalling
was quantified for >300 forks per condition and experiment. The
experiment was repeated three times. Data were analysed using
unpaired two-tailed t test (*P < 0.1, **P < 0.01, ***P < 0.005).Results and discussion
Nuclear localisation of Ru1
Previous confocal laser scanning microscopy (CLSM) and
transmission electron microscopy (TEM) studies indicated that
Ru1 targets nuclear DNA.31 ICP-MS (inductively coupled plasma
mass spectrometry) analysis conrmed high (>70%) cellular
ruthenium content in isolated nuclear fractions of Ru1-treated
oesophageal cancer cells (Fig. S1 in the ESI†) while visualisation
of intracellular MLCT (metal to ligand charge-transfer) emis-
sion of Ru1 in OE21 oesophageal squamous cell carcinoma
(ESCC) cells showed strong overlap with the DNA dye DAPI
(Fig. S2†). In comparison, OE21 cells treated with [Ru(phen)2
(dppz)]2+ (log P ¼ 1.48 (ref. 18)) possessed a 13-fold lower
average cellular Ru content and a 28-fold reduction in nuclear
Ru content than cells treated with Ru1 (Fig. S1a†). In addition to
this, minimal nuclear MLCT emission in [Ru(phen)2(dppz)]
2+-
treated cells was evident by CLSM (Fig. S2†). These results
indicate substantially greater cellular uptake and enhanced
nuclear targeting are demonstrated by Ru1 over
[Ru(phen)2(dppz)]
2+.Ru1 stalls replication fork progression
On the basis of our recent discovery that the multi-intercalator
[Ru(dppz)2(PIP)]
2+ (PIP ¼ 2-(phenyl)imidazo[4,5-f][1,10]phe-
nanthroline) is able to stall replication forks,23 the ability of Ru1
to similarly affect DNA replication was examined by DNA bre
assay. By sequential incorporation of halogenated nucleotides
and immunouorescence staining, this technique allows visu-
alisation of the progression of individual replicating DNA
strands.33,34 Accordingly, OE21 cells were pulse-labelled with the
thymidine analogue CIdU for 30 min before treatment with Ru1
and concomitant labelling with a second thymidine analogue
(IdU) for an additional 30 min, thereby allowing examination of842 | Chem. Sci., 2018, 9, 841–849the direct impact of Ru1 upon replication fork progression
(Fig. 1b). Strikingly, the addition of 21 mM Ru1 (the 24 h IC50
concentration, Table 1) in this manner resulted in a large
decrease in median IdU tract length in DNA bres, indicating
extensive replication fork stalling generated due to the inclu-
sion of the complex (Fig. 1c). This was accompanied by a 1.7-
fold increase in completely stalled/terminated replication forks
(CldU tract only – Fig. 1d). This marked impact on replication
fork progression indicates pronounced and rapid DNA replica-
tion inhibition is generated directly by the addition of Ru1; an
unprecedented result for a substitutionally inert metal complex
that binds DNA solely by mono-intercalation.This journal is © The Royal Society of Chemistry 2018
Table 1 IC50 values (mM) of Ru1, dppz, cisplatin or [Ru(phen)2(dppz)]
2+ towards OE21 human oesophageal squamous cell carcinoma, OE33 and
FLO-1 human oesophageal adenocarcinoma cancer and hSAEC1-KT normal human small airway epithelial cellsa
OE21 OE33 FLO1 hSAEC1-KT
24 h 72 h 24 h 72 h 24 h 72 h 24 h 72 h
Ru1 21  4.2 2.9  1.5 44.5  3.5 27  2.8 42  8 11.5  2.1 78.5  1.3 22  2
dppz 6.5  2.1 3.3  0.4 6.6  2 5.7  0.9 7.5  0.8 1.9  1.1 >10 >10
Cisplatin 22.6  3.6 6.3  0.6 11  1.4 3.25  1 26.5  0.7 4.7  0.7 21.5  5 15.8  2
[Ru(phen)2(dppz)]
2+ >100 >100 >100 >100 >100 34.0  5.7 N.D. N.D.
a Determined by MTT assay (24 or 72 h constant exposure). Data mean of two independent experiments  S.D. N.D. ¼ not done.
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View Article OnlineDNA damage response (DDR) activation by Ru1
To examine DNA damage response (DDR) cell signalling acti-
vation in response to lesions generated by Ru1, we carried out
western blot analyses of protein extracts of OE21 cells using
antibodies against the phosphorylated (activated) forms of
several DDR signalling proteins. In Ru1-treated cells, an
increased level of Chk1 phosphorylation at Ser345 and
phospho-ATR (at Ser428) (ATR¼ ataxia telangiectasia and Rad3-
related protein) at 3 h onwards indicated activation of ATR/
Chk1 signalling (Fig. 2a), in agreement with generation of
replication stress as a result of stalled replication forks.8 An
increased level of phospho-Chk2 (Thr68) and gH2AX (Histone
H2AX phosphorylated at Ser139), both of which are generated
following DNA double-strand damage,8 was also apparent, the
level of each increased with Ru1 exposure time (Fig. 2a).
Comparable temporal DDR activation induced by Ru1 was
observed in wild type p53-containing MCF7 breast cancer cells,
showing that DDR activation occurs independently of p53 status
(Fig. S3†). These results show Ru1 induces both replication
stress and double-strand break (DSB) DDR pathway activation;
a hallmark of replication fork collapse.35Fig. 2 (a) DNA damage response (DDR) activation by Ru1. Whole-cell
extracts of OE21 cells treated with Ru1 (20 mM) for 1, 3, 8 or 24 h were
immunoblotted for activated (phosphorylated, p) p-Chk1 (Ser345),
p-Chk2 (Thr68), p-ATR (Ser428) or gH2AX (pH2AX at Ser139), as
indicated. Total Chk1 and Chk2 protein levels independent of phos-
phorylation status are shown. a-Tubulin or b-actin were used as
loading controls. (b) Relative expression of pChk1 and pChk2 in OE21
cells treated with equipotent (IC50) concentrations of cisplatin (23 mM),
dppz (7 mM) or Ru1 (21 mM) for 3 h, as determined by immunoblotting
and quantified by densitometry (bottom panels). Phosphorylated
protein levels relative to total protein and normalised to control are
presented. gH2AX/b-actin ratio also provided. (c) Impact of Ru1, dppz,
[Ru(phen)2(dppz)]
2+ or cisplatin on viability of OE21 cells, as deter-
mined by MTT assay (24 h incubation time). Mean of quadruplicates 
S.D. and representative of two independent experiments. (d) Immu-
noblotting of gH2AX levels in OE21 cells after 24 h treatment with
cisplatin (Cis), Ru1 or dppz (IC50 and IC70 concentrations).
[Ru(phen)2(dppz)]
2+ treatment also included. b-Actin was used as
a loading control. * 0.25% DMSO.Impact of dppz on replication fork progression
Although X-ray crystal structures have conrmed that DNA
intercalation of RPCs is achieved primarily through the inser-
tion of extended coordinated polypyridyl ligand(s) between base
pairs,11–16 it is unknown whether this effect drives bioactivity. As
poor solubility prevented the use of free tpphz, the cellular
response to free (non-coordinated) dppz (Fig. 1a) – a close
structural analogue of tpphz and the prototypical polypyridyl
intercalating ligand – was also examined. As seen in Fig. 1b–d,
replication fork progression in OE21 cells was impaired aer
the addition of 7 mM dppz, as indicated by a substantial
decrease in IdU tract length and large (three-fold) increase in
levels of stalled forks compared to mock-treated. The similarity
of the impact on replication fork progression for dppz and Ru1
is consistent with the notion that polypyridyl ligand intercala-
tion is responsible for replication inhibition. However,
approximately two-fold greater levels of stalled forks are
generated by dppz than Ru1, indicating a more potent replica-
tion block generated by the organic ligand (Fig. 1d). Examining
DDR activation due to dppz treatment, high pChk1 levels and
decreased levels of the DSB damage marker gH2AX and pChk2This journal is © The Royal Society of Chemistry 2018 Chem. Sci., 2018, 9, 841–849 | 843
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View Article Onlineactivation in comparison to Ru1 treatment were apparent,
indicating reduced DSB damage pathway activation by dppz
(Fig. 2b and d).
In comparison to Ru1 and dppz, [Ru(phen)2(dppz)]
2+
demonstrated substantially reduced impact on cell prolifera-
tion along with no evidence of DDR activation (Fig. 2c and d).
This may be explained by the reduced cellular uptake of
[Ru(phen)2(dppz)]
2+ compared to Ru1 (vide supra). The low
bioactivity and poor nuclear targeting of [Ru(phen)2(dppz)]
2+
are in agreement with other studies.18,32Fig. 3 (a) Representative CLSM images of OE21 cells treated with Ru1
(20 mM, 24 h) visualised at 0, 1, 6 and 24 h after complex removal.
Immunofluorescence staining with anti-gH2AX antibody (white)
provides visualisation of DSB damage. DNA (DAPI) staining included for
reference. Scale bars ¼ 20 mm. (b) Quantification of gH2AX foci/
nucleus for OE21 cells treated as in (a). Data mean S.D. of four or five
micrographs where a minimum of 20 nuclei were counted per image.
(c) Impact of Ru1 (20 mM, 24 h) or dppz (7 mM, 24 h) on cell-cycle
distribution of OE21 cells, as determined by flow cytometric analysis of
DNA content. DNA content in Ru1-treated cells was quantified using
the MLCT emission of Ru1 (see Experimental section). Data are mean
of three independent experiments S.D. (d) AnnexinV staining of OE21
cells treated with cisplatin (23 mM), Ru1 (21 mM) or dppz (7 mM) for 24 h,
as determined by flow cytometry. Average of two independent
experiments  S.D. (e) Clonogenic survival of OE21 cells treated with
Ru1, cisplatin or dppz (24 h incubation time). Average of triplicates 
S.D.Global response to Ru1-induced DNA damage
Depending upon the precise lesion generated, the cellular
response to unrepaired DNA damage is typically either cell-cycle
arrest or cell death.36 High levels of gH2AX foci are retained for
a substantial time aer Ru1 treatment of OE21 cells (Fig. 3a and
b), indicating prolonged DDR activation generated by the
complex and the persistence of unrepaired DNA. Examining
impact on cell-cycle progression, treatment of cycling OE21 cells
with Ru1 induced a two-fold increase in G2/M phase cells
compared to control (Fig. 3c). A distinct cell-cycle response was
induced in response to dppz where instead cells accumulated in
G1 or early S phase (Fig. 3c). In contrast to cisplatin treatment,
limited evidence of annexin-V-positive cells, no observable
karyorrhexis and reduced cleaved caspase 3 expression was
observed in OE21 cells treated with Ru1 (Fig. 3d, S4 and S5†),
indicating low levels of apoptosis. Despite this, a loss of
proliferative capacity as a result of Ru1 treatment was shown by
clonogenic survival assay (Fig. 3e). Furthermore, numerous
growth-arrested Ru1-treated OE21 cells appeared “attened”
with enlarged nuclei (Fig. S5†), a characteristic phenotype of
senescence.37 These results are therefore consistent with
permanent growth arrest being the primary response to Ru1-
generated DNA damage in OE21 cells; although Trypan blue
staining indicates 20% necrotic cell death to accompany this
outcome (Fig. S5a†).
The targeting of genomic DNA without generating high levels
of apoptosis by Ru1 is a distinct cellular response compared to
cisplatin. While at rst this appears surprising, Ru1 and
cisplatin possess different DNA binding modalities (cisplatin
forms covalent Pt–DNA adducts while Ru1 binds non-covalently
via intercalation) and growth arrest in response to DNA-damage
is common, particularly in cells that lack functional p53 and
thus possess a reduced capacity to activate apoptosis.36 It is also
evident that Ru1 demonstrates a different mechanism of action
compared to structurally-related hydrophobic mitochondrial-
targeting RPCs, which induce reactive oxygen species (ROS)-
mediated apoptosis.38–40 As the hydrophilic Ru1 instead
targets nuclear DNA, this illustrates the role of organelle tar-
geting in determining RPC bioactivity.
The differential DDR activation and cell-cycle deregulation
exhibited by Ru1 and dppz are also noteworthy. This may be
rationalised by the greater levels of stalled forks generated by
dppz resulting in a potent G1-S block. For Ru1, fork collapse
instead results in slowed progression through S-phase and the
accumulation of DSB damage, culminating in G2/M checkpoint844 | Chem. Sci., 2018, 9, 841–849activation. This indicates the RuII metal centre inuences
bioactivity and is not solely a “carrier” for the hydrophobic
polypyridyl intercalating ligand. More detailed structural
binding studies of Ru1 and dppz with DNA could be highly
illuminating and provide a molecular basis for these
observations.Ru1 generates metaphase chromosome non-attachment
Close inspection revealed Ru1 induced chromosome misalign-
ment in metaphase OE21 cells (Fig. 4a), possibly asThis journal is © The Royal Society of Chemistry 2018
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View Article Onlinea consequence of non-attachment of sister chromatids to
spindle microtubules. To test this, z-stack confocal analysis and
3D reconstruction conrmed dispersion of condensed chro-
mosomes in Ru1-treated populations with evidence of complete
failure of attachment to the mitotic spindle (Fig. 4b and S6, ESI
Videos 1 and 2†). Misalignment was a consequence of failure of
any kinetochore attachment as no monotelic, syntelic, or mer-
otelic gures were observed. These mitotic aberrationsFig. 4 (a) Misaligned metaphase chromosomes (yellow arrows) in
OE21 cells treated with Ru1 (20 mM, 4 h). After fixation, cells were
stained for a-tubulin (green) and DNA (DAPI, blue). MLCT (metal to
ligand charge-transfer) emission of Ru1 included. (b) 3D representa-
tion of Ru1-treated OE21 cells (20 mM, 24 h) prepared from z-stack
images. Non-aligned chromosomes in labelled cells shown by yellow
arrows. (c) Quantification of aberrant mitoses in Ru1-treated OE21
cells (24 h). Data average of two independent experiments  S.D.,
>200 cells were counted for each condition. (d) CLSM images of
mitotic stages of OE21 cells. (e) Quantification of mitotic sub-pop-
ulations in Ru1-treated OE21 cells (20 mM, 24 h). Data are expressed as
a percentage of total cell population. Data average of two independent
experiments  S.D., >200 cells counted per experiment. (f) Local-
isation of phospho(p)-p44/p42 MAP kinase in metaphase OE21 cells
treated with Ru1 (20 mM, 24 h), as determined by immunofluorescence
(AlexaFluor594, white). DNA staining (DAPI, blue) included for refer-
ence. (g) Formation of micronuclei (red arrows) in OE21 cells treated
with Ru1 (20 mM, 24 h). Data average of two independent experiments
 S.D. where >100 cells were counted for each condition. Scale bars¼
10 mm.
This journal is © The Royal Society of Chemistry 2018accounted for 8% of the total cell population at the IC50
concentration of Ru1 compared with 1.2% for control cells
(Fig. 4c). Examining the impact of Ru1 on m-phase progression,
an increase in prophase, prometaphase and metaphase cells
was observed with an accompanying decrease in anaphase,
telophase and cytokinesis populations (Fig. 4d and e). Increased
levels of chromatin-associated activated (phosphorylated) p44/
42 MAPK (mitogen-activated protein kinases) of aberrant
metaphases indicated activation of the spindle assembly
checkpoint (SAC) by Ru1 (Fig. 4f and S7†) and conrming the
absence of merotelic attachment as the latter do not activate the
SAC.41–43 In addition, treatment with Ru1 resulted in a large
increase in cells containing multiple micronuclei (Fig. 4g and
S8†), indicating that despite activation of the SAC, a signicant
proportion of these cells fail to maintain SAC-induced mitotic
arrest and progress through mitosis; such observations are
a documented consequence of fragmented or detached chro-
mosomes generated during mitosis.44 These results are there-
fore consistent with DNA damage accumulated during mitosis
causing errors in chromosome segregation and spindle
attachment failure, thereby resulting in SAC activation and
delayed metaphase-to-anaphase transition.45 This phenotype
has been observed with other DNA-damaging agents, but these
studies have always required genetic knockdown or co-
treatment with a Chk1 inhibitor to abrogate the G2 check-
point to achieve this outcome.46–48 It is therefore signicant that
Ru1 generates this effect applied as a single-agent.Ru1 demonstrates distinct cancer cell-selectivity
The dual-mode mechanism of action of Ru1 implies that
rapidly-proliferating cells with an elevated mitotic index and/or
mutations of mitotic checkpoint genes (characteristics of many
oesophageal cancers49,50) would be more susceptible to treat-
ment. Accordingly, a panel of p53-decient oesophageal cancer
cell lines defective in Aurora kinase function49,50 were treated
with Ru1 and relative potency assessed by MTT assay, which
measures both cytotoxic and growth inhibitory (cytostatic)
effects.51 Immortalised human small airway epithelial hSAEC1-
KT cells, which are p53-functional, have a slow growth rate and
low mitotic index,52 were used as a control. Comparable cellular
and nuclear uptake of Ru1 in the three cancer cell lines was
observed (Fig. S1†), however, derived half-inhibitory (IC50)
concentrations indicated that the relative potency of Ru1 was
greatest towards OE21 cells (Table 1 and Fig. S9†), which
possess the highest mitotic index and growth rate (Table S1†).
Notably, Ru1 demonstrates a two-fold greater potency than
cisplatin in OE21 cells aer 72 h incubation (Table 1). Encour-
agingly, reduced activity of Ru1 towards normal hSAEC1-KT
cells was observed. In contrast, cisplatin showed comparable
activity towards the cancer cell lines and consistent apoptosis
induction across all cell lines tested, including hSAEC1-KT cells
(Table 1 and Fig. S4b†). Dppz showed consistent activity
towards the three cancer cell lines (Table 1) while the topo-
isomerase inhibitor doxorubicin demonstrated a three-fold
reduction in potency towards OE21 cells compared to OE33 or
FLO-1 cells aer 72 h exposure (Table S2†). These resultsChem. Sci., 2018, 9, 841–849 | 845
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View Article Onlineindicate the cell-selectivity prole demonstrated by Ru1 is not
a general outcome for DNA-damaging agents. The observation
that dppz demonstrated comparable or greater potency than
Ru1 and substantially greater effects than [Ru(phen)2(dppz)]
2+ is
particularly striking as several RPC PDT candidates containing
dppz-derived ligands exert bioactivity by light-activated ligand
dissociation and it is oen assumed their activity is due to the
metal centre coordinating to DNA.26,27,53,54 These results are
therefore consistent with the hypothesis that “uncaged” ligands
play a signicant role in these cases.54
Mutagenicity of Ru1
DNA cross-linking agents such as cisplatin are oen muta-
genic.55 Although increased micronuclei formation indicates
Ru1 induces genotoxic stress, this effect was most apparent in
OE21 cells (Table S3†), a cell line highly susceptible to genotoxic
insult due to chromosomal instability and Aurora kinase B
dysfunction.49 Employing the hypoxanthine phosphorybosyl
transferase (HPRT) forward mutation assay in V79 Chinese
hamster cells we show that although Ru1 does increase muta-
tion frequency above control, the rate is approximately two-fold
lower than for cisplatin (Table 2).
Ru1 radiosensitizes cancer cells via DNA damage
enhancement
Many DNA-targeting drugs are employed as clinical radio-
sensitizers, as they induce specic DNA lesions and/or target
cell-cycle progression to achieve synergy with IR targeted to
cancer cells.1,2 To determine whether Ru1 functions as a radio-
sensitizer, three oesophageal cancer cell lines were pre-treated
with sub-IC50 concentrations of Ru1 (2 mM) for 24 h before
irradiation (0–8 Gy IR; 137Cs-g-rays; dose rate ¼ 0.81 Gy min1)
and relative cytotoxicity assessed by clonogenic survival. Fig. 5a
shows that Ru1 decreases the surviving fraction (S.F.) of all cell
lines in combined treatment compared to radiation alone.
Single-agent Ru1 at this low concentration had a negligible
impact on clonogenic survival (S.F. values > 0.87, Table S4†),
thereby demonstrating the synergistic combination of Ru1 with
IR. Resultant dose modication factors (DMF) at surviving
fractions of 0.1 were 1.19–1.31 for Ru1: a comparable level of
radiosensitization to treatment of the same cell lines with sub-
cytotoxic doses of cisplatin (DMFs at 0.1 ¼ 1.05–1.44). The
concentration required for radiosensitization by Ru1 offersTable 2 Mutation frequency (M. F.) induced by treatment with Ru1 or
cisplatin, as determined by HPRT-forward mutation assay in V79
Chinese hamster cellsa
M.F.b Rel. M.F.c
Control 6.3  2.4 1.0
Ru1 36.7  7.3 5.8
Cisplatin 65.5  11.3 10.4
a Cells were treated with 2 mM of each complex for 24 h. b 6-TG resistant
mutations per 1  105 viable cells. c Ratio of induced to spontaneous
mutations.
846 | Chem. Sci., 2018, 9, 841–849a signicant improvement over previous work using the multi-
intercalator [Ru(dppz)2(PIP)
2+]23 and is similar to more cyto-
toxic Ru(arene)-halide monocationic complexes, which – like
cisplatin – rely upon metal-centred reactivity and the formation
of coordination bonds with DNA.56
DNA replication inhibitors oen act as radiosensitizers by
enhancing IR-induced cytotoxic DSB damage.57,58 Accordingly,
levels of the DSB marker gH2AX59 in cell cultures pre-treated
with Ru1 before exposure to IR were examined. As shown in
Fig. 5b and c, OE21 cells treated with Ru1 before IR (2 Gy)
demonstrated a marked increase in gH2AX foci compared to
single-agent treatment groups. The large increase in gH2AX foci
in concomitant Ru1 and IR treatment indicated a substantial
increase in IR-induced DSB formation compared to either
treatment in isolation. A large increase in gH2AX levels is sus-
tained even at higher doses of IR (8 Gy) and Ru1 (10 or 20 mM)
(Fig. 5d), implying a large therapeutic window exists to combine
the effects of Ru1 and IR.
Compared to work employing RPCs as photosensitizers,
where in situ singlet oxygen or cytotoxic species formation is
required for phototoxicity,25 radiosensitization oen requires
a complimentary cellular mechanism of action to enhance the
DNA-damaging effects of IR.57,58 Considering many small mole-
cules that inhibit DNA replication such as gemcitabine and 5FU
(uorouracil) are potent radiosensitizers,58 it seems likely that the
DNA-targeting properties of Ru1 and subsequent impact upon
replication fork progression play a signicant role in its radio-
sensitizing effects. Furthermore, G2/M phase cells are docu-
mented to be the most sensitive to IR-induced DNA damage,1,2
and so the G2 arrest and metaphase block generated in response
to Ru1 – induced DNA damage would also be predicted to
increase radiosensitivity; a concept supported by the high levels
of gH2AX visible in Ru1-treated metaphase cells exposed to IR
(Fig. 5b). In addition to these effects, work employing cisplatin
has also indicated DNA repair inhibition contributes to radio-
senstization,4 and it will be interesting to measure DNA repair
kinetics in Ru1-radiosensitized cells. Finally, although this work
has established DNA as the primary target of Ru1, the peripheral
coordination site on the tpphz ligand may additionally chelate
metal ions.60,61 In agreement with this principle, the addition of
ten-fold excess Zn2+ and Fe2+ ions to free or DNA-bound Ru1
resulted in a clear decrease in MLCT emission of the complex
(Fig. S10†). Moreover, this effect was reversed by the addition of
the metal chelator EDTA (ethylenediaminetetraacetic acid) for
Zn2+ binding but, interestingly, not Fe2+, thereby demonstrating
a high affinity of Ru1 for ferrous iron. These observations raise
the possibility that Ru1 functions as a metal ion chelator in
addition to binding DNA. While the possibility of intracellular
chelation impacting bioactivity cannot be discounted, this effect
would not be predicted to interfere with intercalative DNA
binding60,61 and the rapid block of replication fork progression by
Ru1 and DDR activation timeframe are consistent with results
obtained using non-chelating DNA-binding compounds such as
[Ru(dppz)2(PIP)
2+].23,62 However, this may be of relevance to other
effects caused by Ru1 as iron chelators have been indicated to
demonstrate radiosensitizing properties.63,64 Future work will
explore these concepts.This journal is © The Royal Society of Chemistry 2018
Fig. 5 (a) Clonogenic survival of OE21, OE33 or FLO-1 cells pre-treated with Ru1 (2 mM, 24 h) before irradiation with 0–8 Gy 137Cs-g-rays. Mean
 SEM of two or three independent experiments. Data were fit to a second order polynomial function (R2 values > 0.99). Data for sub-cytotoxic
doses of cisplatin (Cis) (500 nM OE21 and OE33, 300 nM FLO-1 cells) included (dashed lines). (b) CLSM images of OE21 cells treated with Ru1
(10 mM, 24 h), IR (2 Gy), or both, where IR was applied at the end of Ru1 treatment. Samples were fixed 1 h after irradiation. Immunofluorescence
staining with anti-gH2AX antibody (white) provides visualisation of DSB damage. DNA (DAPI) staining included for reference. Scale bars¼ 10 mm.
(c) Quantification of gH2AX foci/nucleus for OE21 cells treated as in (b). Data mean of two independent experiments  S.D. (d) Immunoblotting
(top) and corresponding densitometry (bottom) of gH2AX levels in OE21 cells treated with Ru1 (24 h) with or without 8 Gy IR after treatment.
Whole-cell extracts were prepared 1 h after irradiation and gH2AX levels were measured relative to b-actin loading controls by densitometry.
Data normalised to untreated cells and are the mean  S.D. of two independent experiments.
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View Article OnlineConclusions
In summary, we present a detailed characterisation of the
cellular response to [Ru(phen)2(tpphz)]
2+ (Ru1) in p53-decient
oesophageal cancer cells, nding this ruthenium(II) metallo-
intercalator induces a potent replication block accompanied
by replication stress and DSB damage repair pathway activation,
without triggering apoptosis. To our knowledge, this is the rst
example of a substitutionally inert ruthenium(II) mono-
intercalator demonstrated to function as a replication inhib-
itor. In parallel to this, metaphase chromosome attachment is
impaired by Ru1. This multi-mode mechanism of action results
in growth inhibition of highly proliferative oesophageal cancer
cells with elevated mitotic indices. Finally, efficient radio-
sensitization through synergistic DNA damage enhancement
illustrates the efficacy of Ru1 in combination with IR, where the
lower mutagenicity and reduced cytotoxicity of Ru1 compared toThis journal is © The Royal Society of Chemistry 2018cisplatin would be predicted to be advantageous in its use
alongside radiotherapy.
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